CTOs on the Move

Edgewise Therapeutics

www.edgewisetx.com

 
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Edgewise Therapeutics raised $95M on 12/08/2020

Similar Companies

Gibraltar Laboratories

Gibraltar Laboratories is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio-ved Pharmaceutical Inc

Bio-ved Pharmaceutical Inc is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FSD Pharma

FSD Pharma is transforming a large facility in Cobourg, Ontario Canada, into the largest hydroponic indoor cannabis production and processing facility in the world, with multiple business units co-supporting each other, operating under a single roof to exploit economies of scale and operational efficiencies. We are growing the future through innovation!

Integrum

Integrum has since its foundation been helping amputees towards an improved quality of life. We specialize in the osseointegration method.

Kyowa Hakko Kirin

Kyowa Kirin North America is a fully integrated specialty pharmaceutical company, where people work together to understand clinical needs and opportunities for innovation that can result in real advances for patients. Since 2018, the North American organization has received approval from the US Food and Drug Administration (FDA) to market 3 first-in-class medicines – achievements we share with the scientific, medical, and advocacy communities who contributed greatly to the success of these programs.